18 terminated. 18 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Terminated 18 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Child Development Disorders, Pervasive: new trials by email Literature Review of Child Development Disorders, Pervasive trials Research Report on Child Development Disorders, Pervasive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD INP105, Placebo - Agitation in Adolescents and Young Adults With ASD | Phase 2 | Terminated | Impel Pharmaceuticals | 8 | 2022-06-23 | 2023-09-28 |
| Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder GWP42006 - Autism Spectrum Disorder | Phase 2 | Terminated | Jazz Pharmaceuticals | 1 | 2020-01-07 | 2022-09-02 |
| Investigation of Mechanisms of Action in Superpower Glass Superpower Glass - Autism Spectrum Disorder, Autism | Phase 1 / Phase 2 | Terminated | Stanford University | 20 | 2019-09-04 | 2023-09-05 |
| Impact of Combined Medication and Behavioral Treatment for ASD & ADHD Amphetamine, ESDM informed parent coaching, Placebo Oral Tablet - Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder | Phase 2 | Terminated | Duke University | 18 | 2018-12-14 | 2022-03-22 |
| Translating Neuroprediction Into Precision Medicine Via Brain Priming Oxytocin, Pivotal Response Treatment, Placebo - Autism Spectrum Disorder | Phase 2 | Terminated | Yale University | 5 | 2018-12-07 | 2022-08-09 |
| A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD) Placebo, RO5285119 - Autism Spectrum Disorder | Phase 2 | Terminated | Hoffmann-La Roche | 339 | 2016-11-21 | 2021-02-08 |
| Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders Melatonin and Donepezil, Placebo - Autism Spectrum Disorder | Phase 2 | Terminated | Stony Brook University | 12 | 2015-06-01 | 2024-06-06 |
| Oxytocin in Adolescents With Autism Spectrum Disorders OCYTOCINA - SPRAY NASAL - Autism Spectrum Disorder | Phase 2 / Phase 3 | Terminated | University of Sao Paulo General Hospital | 30 | 2015-06-01 | 2019-10-28 |
| Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder Trichuris suis ova, Placebo - Autism | Phase 2 | Terminated | Coronado Biosciences, Inc. | 23 | 2014-05-01 | 2015-11-04 |
| A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder IGF-1, Placebo/saline - Autism Spectrum Disorder | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 3 | 2014-05-01 | 2024-02-08 |
| TSO in Pediatric Autistic Spectrum Disorders TSO, Placebo - Autistic Spectrum Disorders | Phase 2 | Terminated | Hadassah Medical Organization | 9 | 2014-04-01 | 2016-02-02 |
| A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism Donepezil, Placebo - Autism Spectrum Disorders | Phase 2 | Terminated | National Institute of Mental Health (NIMH) | 5 | 2013-06-01 | 2017-09-25 |
| Deep rTMS (Repetitive Transcranial Magnetic Stimulation)for Treatment of Autism Symptoms in Children. Transcranial Magnetic Stimulation - Autism | Phase 2 | Terminated | Brainsway | 20 | 2013-01-23 | 2018-04-17 |
| Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Memantine Hydrochloride (HCl) - Autism Spectrum Disorder (ASD), Autism | Phase 2 | Terminated | Forest Laboratories | 747 | 2012-10-01 | 2015-02-16 |
| A Folinic Acid Intervention for Autism Spectrum Disorders Folinic Acid and placebo, Folinic Acid - Autism Spectrum Disorder, Autistic Disorder | Phase 2 | Terminated | University of Arkansas | 99 | 2012-05-01 | 2017-10-17 |
| An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders arbaclofen - Autism Spectrum Disorders | Phase 2 | Terminated | Seaside Therapeutics, Inc. | 32 | 2010-02-01 | 2012-12-20 |
| Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders Omega-3 Fatty Acid - Autism Spectrum Disorder (ASD) | Phase 2 | Terminated | Massachusetts General Hospital | 7 | 2009-11-01 | 2025-03-27 |
| Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behaviors in Autism transcranial magnetic stimulation - Autism, Asperger Disorder | Phase 2 | Terminated | New York State Psychiatric Institute | 10 | 2008-11-01 | 2017-03-24 |
Autism Spectrum Disorder (15) · Autistic Disorder (11) · Asperger Syndrome (3) · Attention Deficit Disorder with Hyperactivity (1) · Behavior (1) · Psychomotor Agitation (1) · Sleep Wake Disorders (1) · Social Skills (1)
Mental Disorders (18) · Neurodevelopmental Disorders (18) · Autism Spectrum Disorder (3) · Behavior (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Aberrant Motor Behavior in Dementia (1) · Attention Deficit and Disruptive Behavior Disorders (1) · Behavioral Symptoms (1) · Dyskinesias (1) · Neurobehavioral Manifestations (1) · Psychomotor Disorders (1)
Donepezil (2) · Oxytocin (2) · Transcranial Magnetic Stimulation (2) · Amphetamine (1) · Equipment and Supplies (1) · Fatty Acids, Omega-3 (1) · Fish Oils (1) · Insulin-Like Growth Factor I (1) · Leucovorin (1) · Melatonin (1) · Memantine (1) · Sodium Chloride (1) · arbaclofen placarbil (1) · cannabidivarin (1) · mecasermin (1)
Brainsway (1) · Coronado Biosciences, Inc. (1) · Duke University (1) · Forest Laboratories (1) · Hadassah Medical Organization (1) · Hoffmann-La Roche (1) · Icahn School of Medicine at Mount Sinai (1) · Impel Pharmaceuticals (1) · Jazz Pharmaceuticals (1) · Massachusetts General Hospital (1) · National Institute of Mental Health (NIMH) (1) · New York State Psychiatric Institute (1) · Seaside Therapeutics, Inc. (1) · Stanford University (1) · Stony Brook University (1)
United States (15) · Israel (2) · Belgium (1) · Brazil (1) · Canada (1) · Colombia (1) · Estonia (1) · France (1) · Hungary (1) · Iceland (1) · Italy (1) · New Zealand (1) · Poland (1) · Serbia (1) · South Africa (1)
Alexander Kolevzon, MD (1) · Alexandra Sporn, MD (1) · Ashura W Buckley, M.D. (1) · Craig Erickson, MD (1) · Denis Sukhodolsky, Ph.D. (1) · Dennis P Wall, PhD (1) · Gagan Joshi, MD (1) · Geraldine Dawson, PhD (1) · Helena P. Brentani, PHD (1) · Itai Berger, MD (1) · Jill Miller-Horn, MD, MS (1) · Jordan Lateiner, MS, MBA (1) · Linmarie Sikich, MD (1) · Matthew Siegel, MD (1)
PMID 27752075, PMID 35793101, PMID 36006807, PMID 37267443, PMID 37811711, PMID 40351246
P50HD093074 (1)